Cogent Biosciences Inc (COGT) - Total Liabilities
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has total liabilities worth $301.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore COGT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Cogent Biosciences Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See COGT free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Cogent Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Cogent Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Churchill Downs Incorporated
NASDAQ:CHDN
|
USA | $6.43 Billion |
|
YTL Corporation Bhd
KLSE:4677
|
Malaysia | RM69.98 Billion |
|
Compagnie du Cambodge
PA:CBDG
|
France | €104.90 Million |
|
Samsung Engineering
KO:028050
|
Korea | ₩5.59 Trillion |
|
Glanbia PLC
IR:GL9
|
Ireland | €2.05 Billion |
|
Ameris Bancorp
NYSE:ABCB
|
USA | $24.03 Billion |
|
SmartSens Technology (Shanghai) Co. Ltd. A
SHG:688213
|
China | CN¥4.92 Billion |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
USA | $71.22K |
Liability Composition Analysis (2015–2025)
This chart breaks down Cogent Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cogent Biosciences Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cogent Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cogent Biosciences Inc (2015–2025)
The table below shows the annual total liabilities of Cogent Biosciences Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $301.24 Million | +320.65% |
| 2024-12-31 | $71.61 Million | +28.72% |
| 2023-12-31 | $55.63 Million | +23.43% |
| 2022-12-31 | $45.08 Million | +151.70% |
| 2021-12-31 | $17.91 Million | +10.21% |
| 2020-12-31 | $16.25 Million | -8.00% |
| 2019-12-31 | $17.66 Million | -31.26% |
| 2018-12-31 | $25.69 Million | +23.46% |
| 2017-12-31 | $20.81 Million | -10.15% |
| 2016-12-31 | $23.16 Million | -8.27% |
| 2015-12-31 | $25.25 Million | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more